Court records indicate that the verdict is the largest awarded so far to a gynecomastia plaintiff in the mass tort program now underway in the Philadelphia Court of Common Pleas. On July 1, 2016, a Pennsylvania jury ordered Johnson & Johnson and Janssen Pharmaceuticals to pay $70 million to a teenager who developed female-like breasts while using Risperdal. BREAKING NEWS: $70 Million Risperdal Verdict Largest So Far Since its FDA approval in 1993, Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals have made billions of dollars in Risperdal sales. Research suggests that it is also frequently prescribed off-label for uses not approved by the FDA however, including the treatment of ADHD.

Like other medications of its kind, Risperdal targets dopamine and serotonin receptors in the brain, and is also approved to treat irritability in children ages 5-to-16 with autism. Food and Drug Administration (FDA) until 2006, court documents show that several Risperdal gynecomastia lawsuit filings involve young boys who allegedly developed the condition Despite the fact that this medication was not approved for pediatric uses by the U.S. Risperdal is an atypical antipsychotic drug approved to treat bipolar disorder and schizophrenia in adults and adolescents between the ages of 10 and 17, among other disorders.

Following a growing body of evidence that ties a popular Johnson & Johnson medication to gynecomastia, a condition referring to male breast growth, an increasing number of Risperdal lawsuit claims alleging this complication have been filed in courts throughout the U.S.

Risperdal recent news